Glaucoma Eye Diseases Glaucoma
Conditions
Interventions
In the treatment part of the study looking at the effect of brimonidine on glaucoma in patients with progressing disease, patients will be randomised to treatment with brimonidine or placebo. This gro
Sponsors
St Mary's Hospital NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Our patient group will be identified from the glaucoma clinics at The Western Eye Hospital according to the following inclusion criteria: 1. For all patient groups: 1.1. Aged 18 years or over 1.2. Clear optical media in the studied eye 1.3. Previous experience at automated perimetry 1.4. No ocular or systemic disease (other than glaucoma in the test group) 1.5. Refractive error not higher than spherical equivalent of 6 D 1.6. Best corrected visual acuity equal to 6/9 or better 2. All subjects will have to have been shown to be able to perform reliable visual field testing using the HFA 640 instrument, central 24-2 program, to yield full thresholds (Deviation, MD-HFA and Pattern Standard Deviation, PSD-HFA), and have had good fundoscopy with assessment of their optic disc 3. Subjects willing and able to make the required study visits 4. All subjects must be able to understand the information describing the study and give informed consent
Exclusion criteria
Exclusion criteria: 1. History of current or severe, unstable or uncontrolled cardiovascular, hepatic or renal disease (e.g., sinus bradycardia, cardiac failure) precluding safe administration of a topical beta antagonists 2. History of bronchial asthma or chronic obstructive airways disease precluding use of a topical beta antagonist 3. Women of childbearing age will be excluded from the study unless they have been surgically sterilised 4. Contact lens wearers will not be allowed to participate in the study 5. Previous ocular surgery such as retinal detachment, multiple surgical procedures including glaucoma 6. Co-existing disease which may affect DARC count e.g., retinal vein occlusion, age-related macular degeneration (AMD)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the DARC count | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary measures are the visual field and optic disc assessment | — |
Countries
United Kingdom
Outcome results
None listed